Direct answer: There is no single tirzepatide-versus-semaglutide price. What a person pays depends on the exact product, dose or presentation, insurance, indication, manufacturer terms, pharmacy channel, and date. Current official self-pay offers range by product and dose, while eligible Medicare beneficiaries may have a separate $50 monthly Bridge pathway. The clinical comparison and the cost comparison answer different questions, and the clinical one comes first.
Dr. Elke Cooke, MD, Emergency Medicine
Pricing boundary: Every dollar figure below is a seller- or program-stated amount observed on July 21, 2026. It is not a permanent quote, list-price claim, coverage guarantee, or recommendation. Recheck official terms at the time of prescribing and dispensing.
Current official self-pay snapshot
| Channel | Displayed amount on verification date | Important condition |
|---|---|---|
| Wegovy injection through NovoCare Pharmacy | $199 for each of the first two monthly fills under a limited introductory offer, then $349 monthly for standard injection doses | Offer displayed through December 31, 2026; terms, eligibility, and dose presentation apply |
| Wegovy HD 7.2 mg injection | $399 monthly | Separate presentation and terms |
| Wegovy tablets | $149 for 1.5 mg; $149 limited offer for 4 mg, then $199; $299 for 9 mg and 25 mg | 4 mg limited offer displayed through August 31, 2026; confirm current oral-product instructions and eligibility |
| Zepbound self-pay vial or KwikPen regular prices | $299 at 2.5 mg; $399 at 5 mg; $499 at 7.5 mg; $699 at 10, 12.5, or 15 mg | Price varies by dose and presentation |
| Zepbound Self Pay Journey offer | $449 for 7.5, 10, 12.5, or 15 mg | Timely refill within 45 days and other program terms apply |
These are not dose recommendations. A lower-dose price is not a reason to select or remain at a dose. Product and dose decisions belong to the prescriber and must follow current labeling and the patient’s response.
Those official numbers are also the yardstick for the many third-party price explainers. Henry Meds, LifeMD, and HealthRX each publish a semaglutide vs tirzepatide cost rundown, and any of them means more when it sits beside the manufacturer and CMS figures rather than standing alone.
Why an insured price can be lower, higher, or unavailable
Commercial plans can differ by employer, state, formulary, indication, deductible stage, prior authorization, and pharmacy. A plan may cover one product and exclude the other. It may require documentation of eligibility, previous interventions, or response. A manufacturer savings card may reduce an eligible commercially insured person’s cost, but maximum savings, duration, pharmacy processing, and exclusions apply.
Novo Nordisk states that eligible commercially insured patients may pay as little as $25 for Wegovy, subject to program terms and maximum savings. “As little as” is not a universal copay. Ask the insurer for a written estimate tied to the exact National Drug Code or presentation, then confirm it at the dispensing pharmacy.
The Medicare GLP-1 Bridge changed the 2026 picture
CMS launched the Medicare GLP-1 Bridge on July 1, 2026. It provides a temporary weight-management access pathway outside Part D for certain eligible Part D beneficiaries through December 31, 2027. CMS states a $50 monthly out-of-pocket amount for covered fills under the Bridge.
Eligibility is detailed, not automatic. Covered products and presentations matter. CMS materials list Wegovy forms and Zepbound KwikPen under the Bridge, while excluding certain Zepbound presentations such as vials and the single-dose pen. When a medicine is prescribed for a Part D-coverable indication, such as Zepbound for qualifying obstructive sleep apnea or Wegovy for qualifying cardiovascular risk reduction, it should be processed through Part D rules rather than treated as a Bridge weight-management fill.
Patients should use the official eligibility process and confirm how the diagnosis is submitted. A headline saying “Medicare now covers GLP-1s” leaves out too much to guide a purchase.
Medicaid and other public coverage require local verification
Medicaid rules vary by state and can change. Eligibility for the program does not prove that a specific weight-management drug is covered. Ask the state plan or managed-care plan whether the exact product and indication are covered, which authorization criteria apply, and which pharmacies can dispense it.
Veterans, military families, and other public-program participants should verify rules through their own benefit rather than extrapolating from commercial savings pages. Manufacturer coupons often exclude government-insured patients.
Calculate total care cost, not only medication price
| Cost component | Question to verify |
|---|---|
| Medication | Is this the FDA-approved product, which presentation, and how many days? |
| Clinical care | Are intake, prescribing, and follow-up included or billed separately? |
| Laboratory work | Which tests are required, why, and which benefit pays? |
| Supplies and shipping | Are needles, alcohol pads, cold shipping, and replacements included? |
| Program fee | Is there a recurring membership charge even if no prescription is filled? |
| Price change | When does an introductory or timely-refill price end? |
| Interruption | What happens financially if the product is unavailable or treatment pauses? |
Build a three-month and twelve-month estimate. Record which numbers are fixed in writing, which depend on continued eligibility, and which can change at renewal.
Do not reverse the clinical sequence
SURMOUNT-5, a head-to-head trial rather than a comparison across separate studies, reported greater average 72-week weight reduction with tirzepatide than with semaglutide in adults with obesity without diabetes. That finding belongs in the effectiveness discussion, not a cost-per-pound calculation. Individual response varies, side effects can interrupt treatment, and weight alone may not be the only clinical goal.
Current product indications also differ, which is where a price comparison stops being like for like. Zepbound now carries a second indication for moderate to severe obstructive sleep apnea in adults with obesity, and semaglutide products carry their own. Cardiovascular risk, sleep apnea, liver disease, diabetes status, and contraindications can each decide the product before cost does. A cheaper product that does not fit the clinical need is not better value.
Why compound prices are not an equivalent row
Compounded semaglutide and tirzepatide are not FDA approved. FDA does not verify their safety, effectiveness, or quality before marketing. A telehealth program may bundle a compound with membership, clinician access, supplies, or shipping, which makes the advertised amount structurally different from a pharmacy price for an approved product.
If compounding is proposed, ask why it is clinically necessary for the identified patient, which ingredient form is used, which licensed pharmacy dispenses it, and how potency, storage, labeling, adverse events, and recalls are handled. Never attach branded clinical-trial outcomes to an unspecified compounded formulation.
In practice a compounded price is a claim about the provider behind it rather than about a molecule, because no approved product sits underneath it to anchor the comparison. Henry Meds, Mochi Health, and FormBlends answer those questions differently, and the answers are what separate one flat monthly figure from another.
A fair five-step comparison
- Confirm the exact product and medically appropriate indication with a prescriber.
- Ask the insurer about coverage, prior authorization, deductible, and preferred pharmacy.
- Check the official manufacturer or CMS program for current eligibility and terms.
- Add all required clinical, laboratory, membership, supply, and shipping costs.
- Recheck the recurring amount and an interruption plan before the first fill.
Keep the nonfinancial questions on the same page as the cost sheet. A total that assumes an indication the patient does not have is not a total.
Do not switch solely to chase a temporary offer
Changing products can create clinical and access complications. A prescriber needs to review the previous dose, last administration, response, adverse effects, other medicines, and the new product’s instructions. Current labeling advises against coadministration with another GLP-1 receptor agonist.
If price is driving a change, confirm that the new channel is durable and that the discount does not disappear after the first fill. There is no universal switching schedule, and the prescriber sets the timing and the starting dose on the new product.
Frequently asked questions
Which is cheaper, Zepbound or Wegovy?
It depends on dose or presentation, program eligibility, insurance, and date. The current official self-pay structures are different and cannot be reduced to one permanent winner.
Can I use a savings card with Medicare?
Manufacturer commercial savings programs generally exclude government insurance. Check CMS and plan-specific pathways instead.
Does a $50 Medicare Bridge amount include every patient?
No. The Bridge has eligibility, diagnosis, product, and presentation rules. Verify through the official process.
Should I pay annually for a telehealth program?
Only after understanding what is included, whether a prescription is promised, the cancellation terms, and the financial effect of a treatment interruption.
Sources
- NovoCare: Wegovy savings, self-pay information, and current cash prices
- Lilly: Zepbound coverage and self-pay information
- CMS, Medicare GLP-1 Bridge: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- CMS, Medicare GLP-1 Bridge information for Part D plans: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
- DailyMed, Zepbound prescribing information: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ZEPBOUND
- DailyMed, Wegovy prescribing information: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=WEGOVY
- FDA, Compounding and the FDA: Questions and Answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from SURMOUNT-5. PubMed: https://pubmed.ncbi.nlm.nih.gov/42012820/
